Open AccessCDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming
Author(s) -
Mengxuan Li,
Nan Che,
Yu Jin,
Jinhua Li,
Yang Wanshan
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s358008
Subject(s) - gene knockdown , glycolysis , downregulation and upregulation , lactate dehydrogenase a , biology , cancer research , carcinogenesis , reprogramming , anaerobic glycolysis , bladder cancer , cancer cell , microbiology and biotechnology , cancer , cell , biochemistry , apoptosis , metabolism , genetics , gene
Aerobic glycolysis plays an important role in bladder cancer (BLCA) progression and chemoresistance. Cyclin-dependent kinase inhibitor-3 (CDKN3), a dual-specificity protein tyrosine phosphatase, has aberrant upregulation in multiple cancer types and is associated with tumorigenesis. However, the role of CDKN3 in BLCA progression and glycolysis has not been elucidated.